Drugs / HH-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07554196 | Jan 2022 → Aug 2023 | cancer | Huahui Health | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-02-22 | Huahui Health | Dosing of First Patient Successfully Completed for Phase I Trial of HH-101 huahuihealth.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HH-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07554196 ↗ |
| Modality | Protein / enzyme biologic | “HH-101 antibody” NCT07554196 ↗ |
| Route | Intravenous | “as an intravenous (IV) infusion” NCT07554196 ↗ |